about
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phaseBosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibFrequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cellsExome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patientsFluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia
P50
Q33396120-A33387A0-C767-4D28-85F8-716CB938A55AQ33414487-6D2D6CB1-E792-4CE4-B73F-BC57F50FB43BQ34210528-B31D10D9-AB14-4412-A66B-E5D172D3D1AFQ35907666-B3F3AB3C-947C-4118-ACDE-A44C72A161BEQ37461942-2E9D2CE8-2C45-46EB-B300-C92999DD82A7Q38113416-D6F11E71-074E-4BB5-800A-DDE6FA2F1B25Q40497868-D5FB483B-EEBC-4DE0-B9F1-9D0E31AAF6BEQ41200962-6FEAE3DC-4216-4798-BE71-603D0EBC278CQ42621930-F3F3D936-DE24-4D1E-B25A-A274C0A35C10Q50101897-32621B01-3D79-4E9C-A54A-D00D8F16FB9AQ54222671-F2F662A2-790C-4B50-B193-3C5010E4A209Q61910225-7A977B7C-2C92-4CF3-B68B-B8ABA0564E06Q64096951-E8A9F8CD-A0AF-4CC8-B869-434A8DF61404Q77495437-D4602D24-BEA2-47DA-9165-D003C4E3CAD6
P50
description
researcher ORCID ID = 0000-0001-9947-2371
@en
wetenschapper
@nl
name
Anna G Turkina
@ast
Anna G Turkina
@es
Anna G Turkina
@nl
Anna Grigorjewna Turkina
@de
Anna Turkina
@en
Анна Григорьевна Туркина
@ru
type
label
Anna G Turkina
@ast
Anna G Turkina
@es
Anna G Turkina
@nl
Anna Grigorjewna Turkina
@de
Anna Turkina
@en
Анна Григорьевна Туркина
@ru
altLabel
Anna G Turkina
@en
Anna Grigoryevna Turkina
@en
Anna Turkina
@de
prefLabel
Anna G Turkina
@ast
Anna G Turkina
@es
Anna G Turkina
@nl
Anna Grigorjewna Turkina
@de
Anna Turkina
@en
Анна Григорьевна Туркина
@ru
P106
P1153
7003959034
P21
P31
P496
0000-0001-9947-2371